TradingKey - Wall Street is navigating a two-day inflation gauntlet. Tuesday's CPI print for April arrived hotter than expected, rattling equity markets from telehealth to nuclear energy. Wednesday morning brings the Producer Price Index (PPI) for April — and if today's Consumer Price Index is any g

TradingKeyWed, May 13

Hims & Hers (HIMS) Q1 2026 Earnings Preview: GLP-1 Pivot, Subscriber Surge & Stock Catalyst Watch

TradingKey - Hims & Hers Health (HIMS) is due to release its Q1 2026 results after the closing bell today. Below, we outline what investors should watch for in today's report.

TradingKeyTue, May 12

Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market

TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

TradingKeyThu, Mar 12

Investing in Health Stock: Will GLP-1 Pill Copycat Restrictions Derail Hims & Hers? Is HIMS Still a Good Choice in 2026?

Hims & Hers' subscription-based business model, coupled with tailored treatment regimens, allows users to maintain lasting engagement, a critical aspect of the company’s growth narrative and a reason why some see Hims & Hers stock as a play on long-term digital health as opposed to a traditional pha

TradingKeyTue, Feb 10

Hims & Hers Health Inc (HIMS): The Opportunity is still Strong and Potent

TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.

TradingKeyMon, Sep 1

Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?

Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

OtherAug 8, 2025

HIMS: When Overvaluation Isn’t What It Seems

TradingKey - The stock market is sending mixed messages about Hims & Hers Health (HIMS). On the plus side, the shares are trading higher by approximately 16% for the day, continuing a red-hot YTD run; on the other, the stock looks overvalued on paper with GAAP P/E and EV/EBITDA multiples several tim

TradingKeyMay 23, 2025